Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Gautam Borthakur; Jorge E. Cortes; Elihu E. Estey; Elias Jabbour; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Tapan Mahendra Kadia; Xuemei Wang; Keyur Patel; Rajyalakshmi Luthra; Charles Koller; Mark Brandt; Farhad Ravandi; Hagop Kantarjian

doi:10.1002/ajh.23795

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Gautam Borthakur, Jorge E. Cortes, Elihu E. Estey, Elias Jabbour, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Tapan Mahendra Kadia, Xuemei Wang, Keyur Patel, Rajyalakshmi Luthra, Charles Koller, Mark Brandt, Farhad Ravandi, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.

Original language	English (US)
Pages (from-to)	964-968
Number of pages	5
Journal	American Journal of Hematology
Volume	89
Issue number	10
DOIs	https://doi.org/10.1002/ajh.23795
State	Published - Oct 1 2014
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.23795

Cite this

Borthakur, G., Cortes, J. E., Estey, E. E., Jabbour, E., Faderl, S., O'Brien, S., Garcia-Manero, G., Kadia, T. M., Wang, X., Patel, K., Luthra, R., Koller, C., Brandt, M., Ravandi, F., & Kantarjian, H. (2014). Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 89(10), 964-968. https://doi.org/10.1002/ajh.23795

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. / Borthakur, Gautam; Cortes, Jorge E.; Estey, Elihu E. et al.
In: American Journal of Hematology, Vol. 89, No. 10, 01.10.2014, p. 964-968.

Research output: Contribution to journal › Article › peer-review

Borthakur, G, Cortes, JE, Estey, EE, Jabbour, E, Faderl, S, O'Brien, S, Garcia-Manero, G, Kadia, TM, Wang, X, Patel, K, Luthra, R, Koller, C, Brandt, M, Ravandi, F & Kantarjian, H 2014, 'Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia', American Journal of Hematology, vol. 89, no. 10, pp. 964-968. https://doi.org/10.1002/ajh.23795

@article{5f23217c40ef46e88ea8028bd09ea15b,

title = "Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia",

abstract = "Despite being considered {"}good-risk{"} acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.",

author = "Gautam Borthakur and Cortes, {Jorge E.} and Estey, {Elihu E.} and Elias Jabbour and Stefan Faderl and Susan O'Brien and Guillermo Garcia-Manero and Kadia, {Tapan Mahendra} and Xuemei Wang and Keyur Patel and Rajyalakshmi Luthra and Charles Koller and Mark Brandt and Farhad Ravandi and Hagop Kantarjian",

note = "Publisher Copyright: {\textcopyright} 2014 Wiley Periodicals, Inc.",

year = "2014",

month = oct,

day = "1",

doi = "10.1002/ajh.23795",

language = "English (US)",

volume = "89",

pages = "964--968",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "10",

}

TY - JOUR

T1 - Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

AU - Borthakur, Gautam

AU - Cortes, Jorge E.

AU - Estey, Elihu E.

AU - Jabbour, Elias

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Kadia, Tapan Mahendra

AU - Wang, Xuemei

AU - Patel, Keyur

AU - Luthra, Rajyalakshmi

AU - Koller, Charles

AU - Brandt, Mark

AU - Ravandi, Farhad

AU - Kantarjian, Hagop

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.

AB - Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.

UR - http://www.scopus.com/inward/record.url?scp=84908053861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908053861&partnerID=8YFLogxK

U2 - 10.1002/ajh.23795

DO - 10.1002/ajh.23795

M3 - Article

C2 - 24990142

AN - SCOPUS:84908053861

SN - 0361-8609

VL - 89

SP - 964

EP - 968

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 10

ER -

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this